Inactive Instrument

News ImmunoCellular Therapeutics Ltd Nyse

Equities

US4525362046

Summary

Unlock all the news on all businesses: Never miss an investment opportunity again!

EOM Pharmaceutical Holdings Provides an Update on its Lead Drug Candidate EOM613	Nov. 07	PR
EOM Pharmaceutical Holdings Announces Topline Results of its COVID-19 Clinical Trial of EOM613 in Brazil	23-09-06	PR
EOM Pharmaceutical Holdings Announces Topline Results of Its Covid-19 Clinical Trial of Eom613 in Brazil	23-09-06	CI
EOM Pharmaceuticals Holdings, Inc. has withdrawn its IPO in the amount of $15 million.	23-08-02	CI
EOM Pharmaceuticals Holdings, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2022	22-12-20	CI
ImmunoCellular Therapeutics Ltd. has Changed its Name to EOM Pharmaceuticals Holdings, Inc	22-11-10	CI
EOM Pharmaceuticals Holdings, Inc. announced that it has received $0.75 million in funding	22-09-11	CI
EOM Pharmaceuticals Holdings, Inc. announced a financing transaction	22-08-25	CI
EOM Pharmaceuticals Holdings, Inc. has filed an IPO in the amount of $25 million.	22-06-24	CI
ImmunoCellular Therapeutics, Ltd. Auditor Raises 'Going Concern' Doubt	22-06-23	CI
ImmunoCellular Therapeutics, Ltd. Auditor Raises 'Going Concern' Doubt	22-02-09	CI
EOM Pharmaceuticals, Inc. And Immunocellular Therapeutics, Ltd. Announce Entry Into And Close Of Definitive Merger Agreement	21-12-02	PR
EOM Pharmaceuticals, Inc. acquired ImmunoCellular Therapeutics, Ltd. in a reverse merger transaction.	21-12-01	CI
ImmunoCellular Therapeutics : Announces Application for Continued Public Quoting on the Over-the-Counter (OTC) Market	21-06-28	PR
Reverse Split: 1 of 10	20-09-15	FA
ImmunoCellular Therapeutics, Ltd.(AMEX:IMUC) dropped from S&P TMI Index	18-10-18	CI
ImmunoCellular Therapeutics, Ltd. Announces Executive Changes, Effective October 15, 2018	18-10-15	CI
ImmunoCellular Therapeutics, Ltd. Announces Unaudited Consolidated Earnings Results for the Second Quarter and Six Months Ended June 30, 2018	18-08-16	CI
ImmunoCellular Therapeutics Is Considering Strategic Alternatives	18-08-13	CI
ImmunoCellular Therapeutics, Ltd. Reports Unaudited Consolidated Earnings Results for the First Quarter Ended March 31, 2018	18-05-14	CI

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

News ImmunoCellular Therapeutics Ltd Nyse

Equities

US4525362046

Summary

Filters